The heritable risk for alcohol use disorder (AUD) is expressed partly through alterations in subjective alcohol response. In this study, we investigated the effects of 2 AUD-risk-associated single nucleotide polymorphisms, GABRA2 rs279858 and GRIK1 rs2832407, on the subjective response to alcohol administered intravenously to healthy social drinkers in a laboratory setting.
T HE IDENTIFICATION of genetic mechanisms influencing alcohol-induced subjective responses may help to guide the development of novel therapeutics for alcohol use disorder (AUD). AUD has a heritability of approximately 50 to 64% (Kendler, 2001; McGue, 1999; Verhulst et al., 2015) . A component of the heritable risk for AUD is expressed as an alteration in the response to alcohol, as individuals with a family history of alcoholism tend to have reduced sedative responses to alcohol (Schuckit, 1994a) , although other studies suggest that heightened stimulant responses to ethanol (EtOH) also contribute to the risk for heavy drinking (King et al., 2014; Morean and Corbin, 2010) . Further, among people with family histories of AUD, those who have these alterations in EtOH subjective response have an elevated risk of developing AUD (King et al., 2014; Schuckit, 1994b) .
Variation in genes influencing the effects of alcohol on the brain may also influence the subjective response to alcohol and subsequently the propensity for developing AUD (Schuckit et al., 2004; Viken et al., 2003) . GABA A receptors are important targets for alcohol in the brain (Krystal et al., 2006) . "Extrasynaptic" subtypes of GABA A receptors are direct targets for alcohol, while synaptic GABA A receptors have low sensitivity to alcohol but respond to GABA that may be released during alcohol administration. Rs279858 is a coding single nucleotide polymorphism (SNP) in exon 5 that produces a synonymous substitution, but a gene expression study in cultured human neural cells showed that the risk allele "C" was associated with significantly reduced mRNA levels for the a 2 subunit of the GABA A receptor (GABRA2), and altered expression of the cluster of 4 GABA A receptor subunit genes on chromosome 4 (Lieberman et al., 2015) . The rs279858*C-allele conveys risk for AUD (cf. reviews by Kranzler and Edenberg, 2010; Kumar et al., 2009 ) and may enhance the stimulant effects or reduce the sedative effects of alcohol in healthy humans Kosobud et al., 2015; Pierucci-Lagha et al., 2005; Roh et al., 2011; Uhart et al., 2013) , although the findings are somewhat contradictory .
EtOH also inhibits NMDA and kainite glutamate receptors (Krystal et al., 2003; Lack et al., 2008) . The GRIK1 gene, which encodes the ionotropic kainate 1 (GLUK1) subunit of kainite receptors, and specifically its intronic SNP rs2832407, is an AUD-risk allele implicated in the antidipsotropic effects of topiramate (Kranzler and Edenberg, 2010; Kranzler et al., 2009 Kranzler et al., , 2014b . SNP rs2832407 moderates positive alcohol-related expectancies (Kranzler et al., 2014a) , suggesting that it influences alcohol effects. However, it is not yet known whether this SNP has functional effects, whether it alters alcohol response in humans, or whether it is the actual causal variant, that is, it could be in linkage disequilibrium with an as yet unknown causal variant.
Several different paradigms of EtOH exposure have been developed to measure and elicit different responses in the laboratory, and these include mainly oral alcohol administration paradigms or those where the EtOH is infused intravenously (Plebani et al., 2012; Ray et al., 2010) . The intravenous alcohol "clamp" paradigm presents some advantages for studies attempting to examine the association of genetic variation to patterns of subjective alcohol response (O'Connor et al., 1998) . By overcoming the variability in oral EtOH absorption, the intravenous EtOH "clamp" paradigm allows one to characterize subjective response to a relatively precisely determined alcohol level, and it enables one to ensure that the target alcohol level will be maintained throughout the assessment period (Ramchandani et al., 2006) . This likely increases the precision of subjective response measurements that occur during the procedure compared to oral alcohol challenge paradigms, and subjects provide subjective response data at the same alcohol level. Further, the subjective response to EtOH measured with the intravenous method is less contaminated by nonspecific neural responses to alcohol-related cues (e.g., seeing a glass of wine) that might confound the signal generated purely through the pharmacologic effects of alcohol (Kareken et al., 2010; Oberlin et al., 2013) . The intravenous "clamp" paradigm has been used successfully in the past to demonstrate significant pharmacogenetic differences in the subjective response to alcohol, and also pharmacogenetic differences in medication response (Ray and Hutchison, 2004; Ray et al., 2007 Ray et al., , 2013 . A critique of intravenous EtOH administration paradigms is that they lack the ecological validity of oral administration paradigms such as the "simulated bar" paradigm (Quinn and Fromme, 2016) .
This study evaluated the effects of AUD-risk-associated polymorphisms of GABRA2 and GRIK1 on the subjective response to EtOH in healthy human subjects using the intravenous EtOH "clamp" procedure. We hypothesized that these 2 risk alleles would render differential effects on the subjective response to alcohol in healthy social drinkers.
MATERIALS AND METHODS
Complete details of the intravenous alcohol procedures used were published previously as the participants were recruited in a previous study which had a primary purpose to examine the effects of family history on alcohol response in the laboratory (Kerfoot et al., 2013) . The institutional review boards of the VA Connecticut Healthcare System and Yale University School of Medicine approved this study. All subjects were recruited through advertisements and provided written informed consent after the nature of the procedures had been fully explained.
Study Subjects
Our sample consists of subjects who participated in a parent study of which we included subjects who were of European American (EA) ancestry and for whom we had DNA available (n = 93). Subjects were between the ages of 21 and 30 years old, without DSM-IV psychiatric or substance use disorder diagnoses (excluding alcohol abuse) as measured by the Structured Clinical Interview for DSM-IV (First et al., 2007) . Subjects were required to have a negative urine toxicology for drugs of abuse on test days and could not be alcohol na€ ıve (for more details, see Kerfoot et al., 2013) . Women were required to have a negative pregnancy test at screening and on every test day. Those who identified 2 first-or second-degree relatives with AUD based on interview were considered to be family history positive. Table 1 shows the characteristics of the study subjects. There were no differences across genotype groups for the 2 SNP variants of GABRA2 and GRIK1 in terms of age, education, age at first drink, percentage of family history positive subjects, and baseline drinking patterns (all p > 0.05). Other baseline drinkingrelated measures such as alcohol expectancies, self-reported alcohol effects, and alcohol-related problems did not differ across genotypes (see Table S1 ).
Study Design
This was a randomized, double-blind, placebo-controlled, between-subject crossover study. Investigators were kept blind to the randomization scheme, which was performed by the research pharmacy service. An ABC scheme was used for randomization to alcohol dose, with the third session (C) kept constant across subjects, the first session (A) randomized with a block procedure, and the second session was the subsequent default alcohol dosage.
All subjects provided blood for DNA extraction and genotyping. Then, each subject underwent 3 test days as described below, corresponding to IV-EtOH administration of 3 "doses" using the IV "clamp" procedure. The 3 test days were at least 3 days apart with administration of either a low dose of EtOH (targeted breathalyzer = 40 mg%), a high dose of EtOH (targeted breathalyzer = 100 mg%), or placebo. Infusion of EtOH was via a solution of 6% by volume EtOH in 0.9% normal saline solution, delivered by a computerized pump at a fixed level ("clamp") to achieve a predetermined breath alcohol concentration (BrAC).
"Intravenous Clamp" Procedure
In the loading phase: The infusion rate was determined using a MatLab Ò version 6.5 calculation package (The MathWorks Inc., Natick, MA), which generated a linear ascension to target BrAC in 20 to 30 minutes based on a subject's individual pharmacokinetic profile based on age, sex, height, and weight. In the plateau phase:
The infusion rate was clamped at a rate estimated to maintain a steady state and then adjusted as needed to maintain the subject's BrAC within AE5 mg% of target BrAC for 60 minutes. BrAC was measured every 2 minutes during the ascension phase and every 2 to 8 minutes during steady state by Alcotest 7410-plus device (Dr€ ager Safety AG & Co. KGaA, L€ ubeck, Germany).
Experimental Procedures
Subjects were scheduled to receive placebo, low-dose EtOH (target BrAC=40 mg%), and high-dose EtOH (target BrAC= 100 mg%), on 3 separate test days, at least 3 days apart, in a randomized order, under double-blind conditions. In order to maintain the blind, the investigators and research staff administering measures were kept blind to subject conditions, but a study nurse was unblinded to the BrAC and made adjustments to the infusion rate. Prior to each test session, participants were instructed not to consume alcohol or caffeine for 48 hours and were asked to fast overnight. They presented to the Biological Studies Unit of the VA Connecticut Healthcare System, West Haven campus, at approximately 9:00 AM. All subjects were given a standardized breakfast at the beginning of each test day and crackers during the test day, as requested. Prior to testing, subjects underwent urine drug screening for toxicology and breathalyzer screening. Provided that these tests were negative, an IV line was placed. Subjects received infusions of placebo or 1 of 2 EtOH doses (low or high) intravenously for approximately 20 to 30 minutes, until the target BrAC was achieved. Once the BrAC was achieved (40 mg% or 100 mg%), it was maintained using the clamp procedure for 60 minutes (O'Connor et al., 1998) . Vital signs (heart rate and blood pressure) were measured at regular intervals during each laboratory session (see Fig. S1 ). Additionally, the respiratory rate was measured 140 minutes prior to the infusion and 200 minutes after reaching the target BrAC.
We used the Biphasic Alcohol Effects Scale (BAES) (Martin et al., 1993) to measure the subjective alcohol response. Measures of subjective alcohol response were obtained at baseline (140 minutes before the IV infusion), 10 minutes after starting the infusion, immediately upon reaching the target alcohol level, and at 30, 80, 110, 140, and 200 minutes after reaching the target alcohol level.
Genotyping DNA was extracted from whole blood using the PureGene kit (Gentra Systems, Minneapolis, MN). We genotyped 2 SNPs, GABRA2 rs279858 and GRIK1 rs2832407, using TaqMan SNP genotyping assays (Life Technologies, Grand Island, NY). All genotypes were obtained in duplicate with consistent results. In our sample, for GABRA2 rs279858 (T/C), the minor allele is "C," and the minor allele frequency (MAF) is 0.446, while for GRIK1 rs2832407 (C/A), the minor allele is "A," and the MAF is 0.339. In the reference population of HapMap-CEU, MAF is 0.473 and 0.385 for GABRA2 rs279858 and GRIK1 rs2832407, respectively. Both SNPs are in Hardy-Weinberg equilibrium (both p > 0.05).
Data Analysis
Both the BAES stimulation and sedation subscale scores were positively skewed with an excess of 0 values. Transformations were unsuccessful in removing the skew and as a result, a repeated-measures nonparametric approach (Brunner et al., 2002) was used, where scores are rank ordered and fitted using a linear mixed model with unstructured covariance matrix followed by an ANOVA-type statistic (ATS) that adjusts the p-values. Both time point and dose were included in the models as categorical variables and entered in the repeated statement with an unstructured block covariance matrix to model the dependence among responses.
Seven time points were included in the analysis relative to the start of 30, 60, 110, 140, 170 , and 230 minutes (see Fig. S1 ). We also recoded the baseline measure at time point À140 minutes (140 minutes before the IV infusion) as a covariate to control for individual baseline differences. The targeted study variables, the SNP markers, were coded as a count of minor alleles, that is, a dose effect model. Other covariates included age, time point, sex, and dose. Sex, dose, and the 2 SNP markers were also exploited to generate and examine 6 pairwise 2-way interaction terms: Sex-byDose, Sex-by-GABRA2, Sex-by-GRIK1, Dose-by-GABRA2, Doseby-GRIK1, and GABRA2-by-GRIK1. The 3 levels of dose (placebo, low, and high doses) and the 7 time points were designated as the within-subject repeated variables in the model and both are categorical variables. Significant effects involving either 1 of the 2 SNPs were further analyzed through linear contrasts to better understand the nature of the effect. These analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC). As there were essentially 2 models used, 1 for stimulation subscale and 1 for sedation subscale effects, the alpha significance level was Bonferroni corrected to 0.025.
RESULTS
Herein, we characterized the genetic effects of GABRA2 rs279858 and GRIK1 rs2832407 on the subjective response to alcohol, and discovered that genetic effects of each 1 of these 2 SNPs on the subjective response to alcohol were influenced by dose and sex differences. In other words, each SNP appeared to pharmacogenetically moderate the subjective response to alcohol. We summarized these findings in Fig. 1 and details are as follows.
BAES Stimulation Subscale in Subjective Response to Alcohol Stimulation Effects
After controlling for age, baseline stimulation score, and time point, there were no main effects of genotype for either GABRA2 or GRIK1. There was a significant 2-way interaction for Dose-by-GABRA2 (p = 0.001) ( Table 2A ). The Sexby-GRIK1 (p = 0.025) interaction was marginally significant after Bonferroni correction (type I alpha <0.025).
Follow-up contrast analyses revealed that the GABRA2 C-allele carriers reported more stimulation than the TT genotype under the high dose compared to the other 2 doses (p = 0.012). In other words, for the Dose-by-GABRA2 interaction, increased stimulation was observed for C-carriers, an AUD-risk variant, under high dose compared to those with the "TT" genotype (0 copies of the C-allele) ( Fig. 2A) . For the Sex-by-GRIK1 interaction, the stimulant responses were higher in sequence from 0 to 1 to 2 copies of the C-allele in males. In other words, there is an allelic dose-response relationship in males, but not in females (p = 0.019) (Fig. 2B) .
BAES Sedation Subscale in Subjective Response to Alcohol Sedation Effects
After controlling for age, baseline sedation score, and time point, there were significant main effects of genotype, GABRA2 C-allele count (p = 0.014) and GRIK1 C-allele count (p = 0.012) on increased alcohol sedation responses, as well as a significant 2-way interaction: Dose-by-GRIK1, between dose and GRIK1 C-allele count (p = 0.004), (Table 2B) . There was no effect of sex or its interactions on the sedation subscale.
For GABRA2-rs279858, increased sedation was observed for C-carriers compared to those with the TT genotype, that Fig. 1 . Result summary. BAES, the Biphasic Alcohol Effects Scale. MAF, minor allele frequency. Three interaction effects which reached significance are listed: Dose x GABRA2, Dose x GRIK1, and GRIK1 x Sex representing the Dose-by-GABRA2 SNP interaction, Dose-by-GRIK1 SNP interaction, and Sex-by-GRIK1 SNP interaction. is, 0 copies of the AUD-risk C-allele (Fig. 3A) . For GRIK1-rs2832407, subjects with the CC genotype had higher sedation compared to those with AC and AA genotypes (Fig. 3B) . Further, the GRIK1 variant interacted with EtOH dose; those with the CC genotype had the most sedation compared to other genotypes and had increasing sedation with increasing EtOH dose (Fig. 3C) . Follow-up contrasts revealed (i) no difference between GRIK1 allele counts at the placebo dose, but at low and high doses, respectively, subjects with 2 copies reported more sedation than subjects with 0 or 1 copy (p = 0.005), and (ii) subjects with 2 copies of GRIK1 reported more sedation than subjects with 0 or 1 copy (p = 0.010).
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DISCUSSION
This study investigated the effects of 2 AUD-risk-associated SNPs, GABRA2 rs279858 and GRIK1 rs2832407, on the subjective response to alcohol and found that each 1 of the 2 SNPs in GABRA2 and GRIK1 appeared to pharmacogenetically moderate the subjective response to alcohol, measured by the BAES in healthy EA social drinkers. Our findings suggest that these SNPs might contribute to the risk of developing AUD by altering the rewarding and reinforcing effects of alcohol. These results provide evidence that the 2 risk alleles were differentially associated with the stimulant and sedative effects of alcohol, suggesting that there might be dissociable features of the genetics and neurobiology of the subjective response to alcohol in humans. The effects of the risk-associated alleles were distinct, and both enhanced the subjective response to EtOH. Thus, when our current results are added to the existing literature on rs279858, and the subjective response to alcohol viewed as a 3-factor construct described by Ray and colleagues (2009) , a somewhat consistent pattern of effects emerges with the C-allele being associated with increased positively reinforcing properties.
The results for GABRA2 rs279858 in this study are consistent with previous findings from an oral alcohol challenge paradigm in which the AUD-risk-associated Ccarriers experienced increased stimulation and euphoriant effects of alcohol. Similar to Arias and colleagues (2014) , in this study there was greater stimulation with alcohol administration for C-allele carriers compared to the TT genotype. As noted earlier, alcohol, at the doses studied here, probably does not act directly at synaptic GABA A receptors bearing the a 2 subunit, although it might stimulate these receptors indirectly by evoking GABA release (Krystal et al., 2006) .
With regard to GABRA2 SNP effects on the BAES sedation subscale, there was no pharmacogenetic effect on sedation response, but the significant main effect suggests a possible behavioral effect not related to alcohol dose. Subjects with 2 AUD-risk C-alleles (CC) reported greater sedation than those that are T allele carriers, even with the placebo dose of alcohol.
While GRIK1 did not influence the subjective stimulant response among the study subjects as a whole, the GRIK1 SNP showed a marginally significant (p = 0.025) interaction with sex on the stimulant response. The allelic dose-response relationship of increasing alcohol stimulant responses (i.e., CC > AC > AA) only occurred in the male participants. This subjective response was not related to the dose of alcohol received and might reflect differences in excitability based on genotype and sex.
In terms of sedative responses, the GRIK1 AUD-risk-associated C-allele was associated with a greater sedative response to EtOH, which was most pronounced for those with the CC genotype. The GRIK1 findings are novel and potentially relevant given the possible contribution of GRIK1 rs2832407 to AUD risk and a variable topiramate treatment response in AUD.
Limitations of the study include that it was conducted in healthy social drinkers, and some AUD-related pharmacogenetic effects may not be represented in this sample. The average age of the subjects (24.3 years) is beyond the peak age of onset for AUD, which may limit the generalizability of the findings, although the average-aged subject was still within a reasonable window of risk for developing the disorder (Grant et al., 2004) . Additionally, only EA subjects were included, and thus, we might not be able to generalize the findings to other populations. EA subjects were identified by self-reported race, with no genomewide genotypes available to implement a more sophisticated adjustment for population stratification. The study's repeated-measures design, which included 8 repeated measures per subject for each of the 3 test days, resulted in reasonable statistical power (Bakeman, 2005 ) despite the small sample size. This study is nevertheless one of the largest to date to evaluate these SNPs using the IV-EtOH clamp procedure. Of note, there was a significant GRIK1-by-GABRA2 modification effect, although 2 of the GRIK1-by-GABRA2 genotype combinations had very small sample sizes (N = 1 and 2), and likely overestimated effect sizes (Gelman and Carlin, 2014) . Thus, we exercised caution and limited the report only to significant singlegene (single-variant) effects.
At least part of the findings in the subjective response to alcohol herein might be due to EtOH's physiological effects (i.e., on heart rate, blood pressure), an open question which is beyond the scope of this study. Also, this study does not explain how these genetic variations cause changes in subjective response to alcohol from a neurobiological standpoint, and this is a possible direction for future studies.
In summary, we found confirmatory evidence that GABRA2 rs279858*C is associated with an altered subjective response to alcohol, possibly explaining its association with an increased risk for developing AUD. GRIK1 rs2832407*C also appears to have a pharmacogenetic interaction with alcohol resulting in an altered subjective response that may convey an increased AUD risk with the C-allele. Further study of the effects of these variants on alcohol-related phenotypes and behaviors may reveal critical information about the pathophysiology of AUD, perhaps leading to better treatments.
SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article: Fig. S1 . Study procedure overview. Table S1 . Baseline drinking patterns including Alcohol Expectancy Questionnaire (AEQ), Negative Alcohol Expectancy Questionnaire (NAEQ), and Self-Rating of the Effects of Alcohol (SRE) total score.
